Eli Lilly Picks Up ImClone For $6.5B
Eli Lilly and Co. will purchase biotechnology company ImClone Systems Inc. in an all-cash deal valued at around $6.5 billion, giving Lilly access to ImClone's blockbuster cancer treatment Erbitux and a...To view the full article, register now.
Already a subscriber? Click here to view full article